Renin system analysis defines the special value of combination antihypertensive therapy using an antirenin agent (CEI) with a long-acting calcium channel blocker (CCB)

American Journal of Hypertension

Volumn 11, Issue 10 II SUPPL., 1998, Pages

  Laragh, John H ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; LOSARTAN; PROPRANOLOL; RENIN INHIBITOR; VALSARTAN;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DRUG MECHANISM; HUMAN; HYPERTENSION; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT PLANNING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RENIN;

EID: 0031772832     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00193-9     Document Type: Conference Paper

References (42)

1. Laragh JH, Ulick S, Januszewicz W, et al: Aldosterone secretion and primary and malignant hypertension. J Clin Invest 1960;39:1091-1106.
2. Laragh JH, Angers M, Kelly WG, Lieberman S: Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II and others on the secretory rate of aldosterone in man. JAMA 1960;174:234-240.
3. Laragh J: The role of aldosterone in man: evidence for regulation of electrolyte balance and arterial pressure by renal-adrenal system which may be involved in malignant hypertension. JAMA 1960;174:293-295.
4. Ames, RP, Borkowski AJ, Sicinski AM, Laragh JH: Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest 1995;44:1171-1186.
5. Laragh JH, Sealey JE, Sommers SC: Patterns of adrenal secretion and urinary excretion of aldosterone and plasma renin activity in normal and hypertensive subjects. Circ Res 1966;18/19(suppl 1):158-174.
6. Sealey JE, Laragh JH: A proposed cybernetic system for sodium and potassium homeostasis: coordination of aldosterone and intrarenal physical factors. Kidney Int 1974;6:281-290.
7. Gavras H, Brunner HR, Laragh JH, et al: An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 1974;291:817-821.
8. Case DB, Wallace JM, Keim HJ, et al: Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin. Am J Med 1976;61: 790-796.
9. Laragh JH, Case DB, Wallace JM, Keim H: Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade. Fed Proc 1977;36:1781-1787.
10. Case DB, Atlas SA, Laragh JH, et al: Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14225, captopril) in hypertensive patients. Prog Cardiovasc Dis 1978;31:195-206.
11. Laragh JH, Letcher RL, Pickering TG: Renin profiling for modern diagnosis and treatment of hypertension. JAMA 1979;241:151-156.
12. Laragh JH, Sealey JE, Niarchos AP, Pickering TG: The vasoconstriction-volume spectrum in normotension and pathogenesis of hypertension. Fed Proc 1982;41: 2415-2423.
13. James GD, Sealey JE, Müller F, et al: Renin relationship to sex, race and age in a normotensive population. J Hypertens 1986;4(suppl 5):S387-S389.
14. Sealey JE, Blumenfeld JD, Bell GM, et al: Presidential address. On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens 1988;6:764-777.
15. James GD, Pickering TG, Laragh JH: Ambulatory blood pressure variation is related to plasma renin activity in borderline hypertensive men. Am J Hypertens 1991;4: 525-528.
16. Gavras H, Brunner HR, Laragh JH, et al: An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 1974;291:817-821.
17. Case DB, Wallace JM, Keim HJ, et al: Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 1977;296:641-646.
18. Laragh JH, Case DB, Atlas SA, Sealey JE: Captopril compared with other anti-renin system agents in hypertensive patients. Its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension 1980;2:586-593.
19. Sealey JE, Laragh JH: Renin and prorenin: advances and declines in methodology. Clin Chem 1996;42:993-994.
20. Laragh JH. Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity, and find the best fit drug regimen, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management. Raven Press, New York, 1995, pp 1813-1836.
21. Blumenfeld JD, Mann SJ, Laragh JH: Clinical evaluation and differential diagnosis of the individual hypertensive patient, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, Chapter 112. Raven Press, New York, 1995, pp 1897-1911.
22. Mann SJ, Blumenfeld JD, Laragh JH: Issues, goals, and guidelines for choosing first-line and combination antihypertensive drug therapy, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, Chapter 150. Raven Press, New York, 1995, pp 2531-2542.
23. Brunner HR, Laragh JH, Baer L, et al: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;186:441-449.
24. Tobian LJ, Lang J, Ulm K, et al: Potassium reduces cerebral hoemorrhage and death rates in hypertensive rats, even when blood pressure is not lowered. Hypertension 1985;7(suppl I):I110-I114.
25. Khaw, K-T, Barrett-Connor E: Dietary potassium and stroke-associated mortality. A 12 year prospective population study. N Engl J Med 1987;316:235-240.
26. 8-angiotensin II. N Engl J Med 1976;295: 1175-1177.
27. Lopez-Overjero JA, Saal SD, D'Angelo WA, et al: reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979;300:1417-1418.
28. Volpe M, Carnargo MJF, Mueller FB, et al: Relation of plasma renin to end organ damage and to protection of K+ feeding in stroke-prone hypertensive rats. Hypertension 1990;15:318-326.
29. Alderman MH, Madhavan S, Ooi WL, et al: Association of renin/sodium profile with risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
30. von Lutterotti N, Camargo MJF, Campbell WG Jr, et al: Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. J Hypertens 1992;10:949-957.
31. Camargo MJ, von Lutterotti N, Campbell WG Jr, et al: Control of blood pressure and end-organ damage in maturing salt loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993;11:31-40.
32. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH: Renin is not synthesized by cardiac and extrarenal vascular tissues: a review of experimental evidence. Circulation 1994;89:458-470.
33. Gruppo Italiano per lo Studio della Sopiavvivenza nell'Infarto miocardio: GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
34. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: Randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium silfate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345: 669-685.
35. Swedberg K, Eneroth P, Kjekshus J, Whilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-1736.
36. Bellet M, Sassano P, Guyenne T, et al: Convertingenzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine. Br J Clin Pharmacol 1987;24:465-472.
37. Jakobsen J, Glaus L, Fraf P, et al: Unmasking of the hypertensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril. J Hypertens 1992;10:1045-1051.
38. Stornello M, Di Rao G, lachello M, et al: Hemodynamic and humoral interactions between captopril and nifedipine. Hypertension 1983;(suppl III):154-156.
39. Bellet M, Sassano P, Guyenne T: Sympatho-inhibitory effect of angiotensin converting enzyme inhibition during counter-regulation induced by dihydropyridine (abst). J Hypertens 1987;5(suppl 5):S583.
40. Brouwer RM, Bolli P, Erne P, et al: Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol 1985;7(suppl 1):S88-S91.
41. Fitscha P, Meisner W, Hitzenberger G: Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension. J Cardiovasc Pharmacol 1991;18(suppl 3):S12-S14.
42. Frishman WH, Ram CV, McMahon FG, et al, for the Benazepril/Amlodipine Study Group: Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. J Clin Pharmacol 1995;35:1060-1066.